{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:10:19Z","timestamp":1790349019231,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T00:00:00Z","timestamp":1730592000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40261-024-01405-8","type":"journal-article","created":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T01:00:06Z","timestamp":1730595606000},"page":"849-861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"44","author":[{"given":"Lisbet","family":"Westergaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Alifrangis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Veit","family":"Coester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klitgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels R.","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"N\u00f8rgreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00eds M. P.","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte B.","family":"Steensgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Vegge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Plum-M\u00f6rschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,3]]},"reference":[{"key":"1405_CR1","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925\u201366. https:\/\/doi.org\/10.1007\/s00125-022-05787-2.","journal-title":"Diabetologia"},{"key":"1405_CR2","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024. Diabetes Care 2024;47(Suppl 1):S158\u201378. https:\/\/doi.org\/10.2337\/dc24-S009.","DOI":"10.2337\/dc24-S009"},{"issue":"Suppl 1","key":"1405_CR3","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S1262-3636(16)30006-4","volume":"41","author":"B Cariou","year":"2015","unstructured":"Cariou B. Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association. Diabetes Metab. 2015;41(Suppl 1):S28\u201335. https:\/\/doi.org\/10.1016\/S1262-3636(16)30006-4.","journal-title":"Diabetes Metab"},{"key":"1405_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/dom.12025","volume":"15","author":"R Balena","year":"2013","unstructured":"Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab. 2013;15:485\u2013502. https:\/\/doi.org\/10.1111\/dom.12025.","journal-title":"Diabetes Obes Metab"},{"key":"1405_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s12325-018-0868-9","volume":"36","author":"L Perreault","year":"2019","unstructured":"Perreault L, Rodbard H, Valentine V, Johnson E. Optimizing fixed-ratio combination therapy in type 2 diabetes. Adv Ther. 2019;36:265\u201377. https:\/\/doi.org\/10.1007\/s12325-018-0868-9.","journal-title":"Adv Ther"},{"key":"1405_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s13300-021-01189-6","volume":"13","author":"WH Polonsky","year":"2022","unstructured":"Polonsky WH, Arora R, Faurby M, Fernandes J, Liebl A. Higher rates of persistence and adherence in patients with type 2 diabetes initiating once-weekly vs daily injectable glucagon-like peptide-1 receptor agonists in US clinical practice (STAY Study). Diabetes Ther. 2022;13:175\u201387. https:\/\/doi.org\/10.1007\/s13300-021-01189-6.","journal-title":"Diabetes Ther."},{"key":"1405_CR7","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.2147\/PPA.S106821","volume":"10","author":"WH Polonsky","year":"2016","unstructured":"Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adher. 2016;10:1299\u2013307. https:\/\/doi.org\/10.2147\/PPA.S106821.","journal-title":"Patient Prefer Adher"},{"key":"1405_CR8","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s12325-018-0819-5","volume":"35","author":"J Okemah","year":"2018","unstructured":"Okemah J, Peng J, Qui\u00f1ones M. Addressing clinical inertia in type 2 diabetes mellitus: a review. Adv Ther. 2018;35:1735\u201345. https:\/\/doi.org\/10.1007\/s12325-018-0819-5.","journal-title":"Adv Ther"},{"key":"1405_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1463-1326.2010.01327.x","volume":"13","author":"WH Polonsky","year":"2011","unstructured":"Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13:144\u20139. https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01327.x.","journal-title":"Diabetes Obes Metab"},{"key":"1405_CR10","doi-asserted-by":"publisher","first-page":"8942","DOI":"10.1021\/acs.jmedchem.1c00257","volume":"64","author":"TB Kjeldsen","year":"2021","unstructured":"Kjeldsen TB, Hub\u00e1lek F, Hj\u00f8rringgaard CU, et al. Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans. J Med Chem. 2021;64:8942\u201350. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00257.","journal-title":"J Med Chem"},{"key":"1405_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002301","volume":"9","author":"E Nishimura","year":"2021","unstructured":"Nishimura E, Pridal L, Glendorf T, et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care. 2021;9:e002301. https:\/\/doi.org\/10.1136\/bmjdrc-2021-002301.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1405_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/dom.14871","volume":"25","author":"A Philis-Tsimikas","year":"2023","unstructured":"Philis-Tsimikas A, Bajaj HS, Begtrup K, et al. Rationale and design of the phase 3a development programme (ONWARDS 1\u20136 trials) investigating once-weekly insulin icodec in diabetes. Diabetes Obes Metab. 2023;25:331\u201341. https:\/\/doi.org\/10.1111\/dom.14871.","journal-title":"Diabetes Obes Metab"},{"key":"1405_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJMoa2303208","volume":"389","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Bain SC, Gowda A, et al. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med. 2023;389:297\u2013308. https:\/\/doi.org\/10.1056\/NEJMoa2303208.","journal-title":"N Engl J Med"},{"key":"1405_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jama.2023.11313","volume":"330","author":"I Lingvay","year":"2023","unstructured":"Lingvay I, Asong M, Desouza C, et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial. JAMA. 2023;330:228\u201337. https:\/\/doi.org\/10.1001\/jama.2023.11313.","journal-title":"JAMA"},{"key":"1405_CR15","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau J, Bloch P, Sch\u00e4ffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58:7370\u201380. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00726.","journal-title":"J Med Chem"},{"key":"1405_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","volume":"45","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1\u20137 trials. Diabetes Metab. 2019;45:409\u201318. https:\/\/doi.org\/10.1016\/j.diabet.2018.12.001.","journal-title":"Diabetes Metab"},{"key":"1405_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40262-017-0589-2","volume":"57","author":"RP Dash","year":"2018","unstructured":"Dash RP, Rais R, Srinivas NR. Key pharmacokinetic essentials of fixed-dosed combination products: case studies and perspectives. Clin Pharmacokinet. 2018;57:419\u201326. https:\/\/doi.org\/10.1007\/s40262-017-0589-2.","journal-title":"Clin Pharmacokinet"},{"key":"1405_CR18","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/Corr. 20 January 2010. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 27 Sept 2024."},{"key":"1405_CR19","unstructured":"Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for industry. Bioavailability and bioequivalence studies submitted in NDAs or INDs\u2014general considerations. 2014. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioavailability-and-Bioequivalence-Studies-Submitted-in-NDAs-or-INDs-%E2%80%94-General-Considerations.pdf. Accessed 27 Sept 2024."},{"key":"1405_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40261-022-01243-6","volume":"43","author":"L Plum-M\u00f6rschel","year":"2023","unstructured":"Plum-M\u00f6rschel L, Andersen LR, Hansen S, et al. Pharmacokinetic and pharmacodynamic characteristics of insulin icodec after subcutaneous administration in the thigh, abdomen or upper arm in individuals with type 2 diabetes mellitus. Clin Drug Investig. 2023;43:119\u201327. https:\/\/doi.org\/10.1007\/s40261-022-01243-6.","journal-title":"Clin Drug Investig"},{"key":"1405_CR21","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s13300-019-0581-y","volume":"10","author":"RV Overgaard","year":"2019","unstructured":"Overgaard RV, Delff PH, Petri KCC, Anderson TW, Flint A, Ingwersen SH. Population pharmacokinetics of semaglutide for type 2 diabetes. Diabetes Ther. 2019;10:649\u201362. https:\/\/doi.org\/10.1007\/s13300-019-0581-y.","journal-title":"Diabetes Ther."},{"key":"1405_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1042\/bj3120725","volume":"312","author":"P Kurtzhals","year":"1995","unstructured":"Kurtzhals P, Havelund S, Jonassen I, et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J. 1995;312:725\u201331. https:\/\/doi.org\/10.1042\/bj3120725.","journal-title":"Biochem J"},{"key":"1405_CR23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1021\/js950412j","volume":"85","author":"P Kurtzhals","year":"1996","unstructured":"Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Ribel U, Markussen J. Albumin binding and time action of acylated insulins in various species. J Pharm Sci. 1996;85:304\u20138. https:\/\/doi.org\/10.1021\/js950412j.","journal-title":"J Pharm Sci"},{"key":"1405_CR24","unstructured":"Ozempic (semaglutide). European Medicines Agency. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ozempic-epar-product-information_en.pdf. Accessed 27 Sept 2024."},{"key":"1405_CR25","unstructured":"ClinicalTrials.gov ID: NCT05352815. A 52 week study comparing the efficacy and safety of once weekly IcoSema and once weekly insulin icodec, both treatment arms with or without oral anti diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily basal insulin (COMBINE 1). https:\/\/clinicaltrials.gov\/study\/NCT05352815. Accessed 27 Sept 2024."},{"key":"1405_CR26","unstructured":"ClinicalTrials.gov ID: NCT05259033. A 52 week study comparing the efficacy and safety of once weekly IcoSema and once weekly semaglutide, both treatment arms with or without oral anti diabetic drugs, in participants with type 2 diabetes inadequately controlled with a GLP 1 receptor agonist (COMBINE 2). https:\/\/clinicaltrials.gov\/study\/NCT05259033. Accessed 27 Sept 2024."},{"key":"1405_CR27","unstructured":"ClinicalTrials.gov ID: NCT05013229. A 52 week study comparing the efficacy and safety of once weekly IcoSema and daily insulin glargine 100 units\/mL combined with insulin aspart, both treatment arms with or without oral anti diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily basal insulin (COMBINE 3). https:\/\/clinicaltrials.gov\/study\/NCT05013229. Accessed 27 Sept 2024."},{"key":"1405_CR28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S2213-8587(23)00093-1","volume":"11","author":"A Philis-Tsimikas","year":"2023","unstructured":"Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023;11:414\u201325. https:\/\/doi.org\/10.1016\/S2213-8587(23)00093-1.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1405_CR29","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(23)00520-2","volume":"401","author":"C Mathieu","year":"2023","unstructured":"Mathieu C, \u00c1sbj\u00f6rnsd\u00f3ttir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet. 2023;401:1929\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(23)00520-2.","journal-title":"Lancet"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01405-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01405-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01405-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T07:44:41Z","timestamp":1731570281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01405-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1405"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01405-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"14 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"L.W., L.A., S.T.B., T.K., N.R.K., E.N., L.N., T.M.P.R., D.B.S. and A.V. are employees and shareholders of Novo Nordisk. H.V.C. has no conflicts of interest to disclose. L.P.-M. is an employee and shareholder of Profil. Profil received research funds from Adocia, AstraZeneca, Betagenon, Biocon, Bioton, Crinetics, Eli Lilly, Genova, Nanexa, NeoDyne, Novo Nordisk, Sanofi, Spiden and Zealand Pharma. L.P.-M. received speaker honoraria from Eli Lilly, Gan and Lee Pharmaceuticals and Novo Nordisk.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Individual participant data will be shared in data sets in a de-identified\/anonymised format. Datasets from Novo Nordisk sponsored clinical research completed after 2001 for product indications approved in both the EU and USA will be shared. Study protocol and redacted clinical study report will be available according to Novo Nordisk data sharing commitments. The data will be available permanently after research completion and approval of product and product use in both EU and USA. There is no end date. Data will be shared with bona fide researchers submitting a research proposal requesting access to data for use as approved by the independent review board according to the independent review board charter (see novonordisk-trials.com). The data will be made available on a specialised SAS data platform. Individual data from animal studies and in vitro studies will be shared upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The clinical study was approved by an independent ethics committee (\u00c4rztekammer Nordrhein, D\u00fcsseldorf, Germany; approval ID 2018242; approval date 12 November 2018). Animal studies were performed according to the Danish Act on Experiments on Animals, the Appendix A of the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes (ETS 123), and European Union Directive 2010\/63. The animal studies were performed under licenses granted by the Danish national Animal Experiments Inspectorate (no. 2010\/561-1786 and no. 2015-15-0201-00540).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the clinical study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"L.W., N.R.K., L.N. and T.M.P.R. contributed to clinical study data analysis, critical manuscript revision and final manuscript approval; L.A., S.T.B., T.K., E.N., D.B.S. and A.V. contributed to animal and in vitro study design, data analysis, critical manuscript revision and final manuscript approval; H.V.C. and L.P.-M. contributed to clinical study data collection, critical manuscript revision and final manuscript approval.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}